Show simple item record

dc.contributor.authorMcCallion, C
dc.contributor.authorPeters, AD
dc.contributor.authorBooth, A
dc.contributor.authorRees-Unwin, K
dc.contributor.authorAdams, J
dc.contributor.authorRahi, R
dc.contributor.authorPluen, A
dc.contributor.authorHutchinson, CV
dc.contributor.authorWebb, SJ
dc.contributor.authorBurthem, J
dc.date.accessioned2019-10-01T08:51:53Z
dc.date.issued2019-07-23
dc.identifier.issn2473-9529
dc.identifier.issn2473-9537
dc.identifier.urihttp://hdl.handle.net/10026.1/14951
dc.description.abstract

<jats:title>Abstract</jats:title> <jats:p>CXC chemokine receptor 4 (CXCR4) is overexpressed by a broad range of hematological disorders, and its interaction with CXC chemokine ligand 12 (CXCL12) is of central importance in the retention and chemoprotection of neoplastic cells in the bone marrow and lymphoid organs. In this article, we describe the biological evaluation of a new CXCR4-targeting and -antagonizing molecule (BAT1) that we designed and show that, when incorporated into a liposomal drug delivery system, it can be used to deliver cancer therapeutics at high levels to chronic lymphocytic leukemia (CLL) cells. CXCR4 targeting and antagonism by BAT1 were demonstrated alone and following its incorporation into liposomes (BAT1-liposomes). Antagonism of BAT1 against the CXCR4/CXCL12 interaction was demonstrated through signaling inhibition and function blocking: BAT1 reduced ERK phosphorylation and cell migration to levels equivalent to those seen in the absence of CXCL12 stimulation (P &amp;lt; .001). Specific uptake of BAT1-liposomes and delivery of a therapeutic cargo to the cell nucleus was seen within 3 hours of incubation and induced significantly more CLL cell death after 24 hours than control liposomes (P = .004). The BAT1 drug-delivery system is modular, versatile, and highly clinically relevant, incorporating elements of proven clinical efficacy. The combined capabilities to block CXCL12-induced migration and intracellular signaling while simultaneously delivering therapeutic cargo mean that the BAT1-liposome drug-delivery system could be a timely and relevant treatment of a range of hematological disorders, particularly because the therapeutic cargo can be tailored to the disease being treated.</jats:p>

dc.format.extent2069-2081
dc.format.mediumPrint
dc.languageen
dc.language.isoen
dc.publisherAmerican Society of Hematology
dc.subjectAntineoplastic Agents
dc.subjectCell Survival
dc.subjectChemokine CXCL12
dc.subjectDEAD-box RNA Helicases
dc.subjectDoxorubicin
dc.subjectDrug Carriers
dc.subjectDrug Delivery Systems
dc.subjectHumans
dc.subjectLeukemia
dc.subjectLeukemia, Lymphocytic, Chronic, B-Cell
dc.subjectLiposomes
dc.subjectLymphocytes
dc.subjectMolecular Structure
dc.subjectMolecular Targeted Therapy
dc.subjectProtein Binding
dc.subjectReceptors, CXCR4
dc.titleDual-action CXCR4-targeting liposomes in leukemia: function blocking and drug delivery
dc.typejournal-article
dc.typeJournal Article
dc.typeResearch Support, Non-U.S. Gov't
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/31292126
plymouth.issue14
plymouth.volume3
plymouth.publisher-urlhttp://dx.doi.org/10.1182/bloodadvances.2019000098
plymouth.publication-statusPublished
plymouth.journalBlood Advances
dc.identifier.doi10.1182/bloodadvances.2019000098
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeUnited States
dcterms.dateAccepted2019-05-24
dc.rights.embargodate2021-4-17
dc.identifier.eissn2473-9537
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1182/bloodadvances.2019000098
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2019-07-23
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV